例儿童急性单核细胞性白血病疗效分析精品课件

7575例例儿儿儿儿童急性童急性单单单单核核细细细细胞性白胞性白 血病血病疗疗疗疗效分析效分析 上海儿童医学中心血液肿瘤科 徐应永 陈静 薛惠良 汤静燕 潘慈 江华 董璐 叶启东 罗长缨 周敏 顾龙君 Your company sloganYour company slogan 研研究背景：M5预预后？ 儿童AML5年EFS 5060%，M0、M6、M7普遍认为 预后差； M5预后报道差异较大，5年EFS 17.9-56.0%； 预后如何？ 相关危险因素？ 最佳治疗策略？ Your company sloganYour company slogan 不同研研究组儿组儿 童M5预预后差异异 研究组组方案简简称总总数百分比5年EFS率AML5年EFS 率 M5预预后 POGPOG-882149318.1%21.14.5%32.72.2%差(P0.0528.08.8%0.05 女性2681.0%42.110.4% 年龄龄 0.0562.517.1%10岁）、1疗 程后骨髓原幼稚细胞比例（15%）、2个疗程未CR是 主要影响因素； 婴儿M5预后良好； 5年EFS为62.517.1%，2疗程CR率达83.3%； 化疗后骨髓检查 一般在骨髓恢复造血时进行； Your company sloganYour company slogan 讨论讨论 ：SIRS Your company sloganYour company slogan 结论结论 : 后续最佳治疗方案？ Your company sloganYour company slogan N=20（5例移植，15例化疗疗），P=0.024 1疗程后15%选择移植优于单纯化疗 Your company sloganYour company slogan 讨论讨论 ： 15%预后差，5-15%有待讨论 Your company sloganYour company slogan 关关于移植治疗疗： 诊断 第1疗程 5-15% 化疗 CR 未CR MSD 化疗 15% MUD /MMSD Your company sloganYour company slogan 谢谢谢谢 Your company sloganYour company slogan Zs*y0D6JbOhUnZs*y0D6JbOhUmZs*x0D6JbOhUmZs*x0D6IbOhTmZs*x0D6IbOhTmZs&x0D6IbOhTmZs&x0D5IbOgTmZs&x0D5IbOgTmZr&x0C5IbOgTmZr&x0C5IbNgTmYr&x0C5IbNgTmYr&x+C5IaNgTmYr&x+C5IaNgTlYr&w+C5IaNgTlYr&w+C5HaNgSlYr&w+C5HaNgSlYr%w+C5HaNgSlYr%w+C4HaNfSlYr%w+C4HaNfSlYq%w+B4HaNfSlYq%w+B4HaMfSlXq%w+B4HaMfSlXq%w-B4H9MfSlXq%w-B4H9MfSkXq%v-B4H9MfSkXq%v-B4G9MfRkXq%v-B4G9MfRkXq$v-B3G9MfRkXq$v-B3G9MeRkXq$v-B3G9MeRkXp$v-A3G9MeRkXp$v- A3G9LeRkWp$v-A3G9LeRkWp$v)A3G8LeRkWp$v)A3G8LeRjWp$u)A3G8LeRjWp$u)A3F8LeQjWp$u)A3F8LeQjWp!u)A2F8LeQjWp!u)A2F8LdQjWp!u)A2F8LdQjWo!u)z2F8LdQjWo!u)z2F8KdQjVo!u)z2F8KdQjVo!u(z2F7KdQjVo!u(z2F7KdQiVo!t(z2F7KdQiVo!t(z2E7KdPiVo!t%w-B4H9MfSkXq%w-B4H9MfSkXq%v-B4G9MfSkXq%v-B4G9MfRkXq$v-B4G9MfRkXq$v-B3G9MeRkXq$v-B3G9MeRkXp$v-A3G9MeRkXp$v-A3G9LeRkWp$v- A3G9LeRkWp$v)A3G9LeRkWp$v)A3G8LeRjWp$v)A3G8LeRjWp$u)A3F8LeRjWp$u)A3F8LeQjWp!u)A3F8LeQjWp!u)A2F8LdQjWp!u)A2F8LdQjWo!u)z2F8LdQjWo!u)z2F8KdQjVo!u)z2F8KdQjVo!u(z2F8KdQjVo!u(z2F7KdQiVo!u(z2F7KdQiVo!t(z2E7KdQiVo!t(z2E7KdPiVo#t(z2E7KdPiVo#t(z1E7KcPiVo#t(z1E7KcPiVn#t(y1E7KcPiVn#t(y1E7JcPiUn#t(y1E7JcPiUn#t*y1E6JcPiUn#t*y1E6JcPhUn#t*y1E6JcPhUn#s*y1D6JcPhUn#s*y1D6JcOhUnZs*y1D6JcOhUnZs*y0D6JbOhUnZs*y0D6JbOhUmZs*x0D6JbOhUmZs*x0D6IbOhTmZs*x0D6IbOhTmZs&x0D5Ib OhTmZs&x0D5IbOgTmZs&x0D5IbOgTmZr&x0C5IbOgTmZr&x0C5IbNgTmYr&x0C5IbNgTmYr&x+C5IaNgTmYr&x+C5IaNgTlYr&w+C5IaNgTlYr&w+C5HaNgSlYr&w+C5HaNgSlYr%w+C4HaNgSlYr%w+C4HaNfSlYq%w+C4HaNfSlYq%w+B4HaNfSlYq%w+B4HaMfSlXq%w+B4HaMfSlXq%w-B4H9MfSlXq%w-B4H9MfSkXq%v-B4H9MfSkXq%v-B4G9MfRkXq%v-B4G9MfRkXq$v-B3G9MfRkXq$v-B3G9MeRkXp$v-B3G9MeRkXp$v-A3G9MeRkXp$v-A3G9LeRkWp$v- A3G9LeRkWp$v)A3G8LeRkWp$v)A3G8LeRjWp$u)A3G8LeRjWp$u)A3F8LeQjWp$u)A3F8LeQjWp!u)A2F8LeQjWp!u)A2F8LdQjWo!u)A2F8LdQjWo!u)z2F8KdQjWo!u)z2F8KdQjVo!u)z2F8KdQjVo!u(z2F7KdQjVo!u(z2F7KdQiVo!t(z2F7KdQiVo!t(z2E7KdPiVo!t(z2E7KdPiVo#t(z1E7KdPiVo#t(z1E7KcPiVn#t(z1E7KcPiVn#t(y1E7JcPiVn#t(y1E7JcPiUn#t(y1E7JcPiUn#t*y1E6JcPiUn#t*y1E6JcPhUn#s*y1E6JcPhUn#s*y1D6JcOhUn#s*y1D6JcOhUnZs*y0D6JcOhUnZs*y0D6JbOhUmZs*y0D6JbOhUmZs*x0D6IbOhUmZs*x0D6IbOhTmZs&x0D6IbOhTmZs&x0D5I bOhTmZs&x)z2F8KdQjVo!u)z2F8KdQjVo!u(z2F7KdQjVo!u(z2F7KdQiVo!t(z2F7KdQiVo!t(z2E7KdQiVo!t(z2E7KdPiVo#t(z2E7KdPiVo#t(z1E7KcPiVo#t(z1E7KcPiVn#t(y1E7KcPiVn#t(y1E7JcPiUn#t(y1E7JcPiUn#t*y1E6JcPiUn#t*y1E6JcPhUn#s*y1E6JcPhUn#s*y1D6JcPhUn#s*y1D6JcOhUnZs*y1D6JcOhUnZs*y0D6JbOhUnZs*y0D6JbOhUmZs*x0D6JbOhUmZs*x0D6IbOhTmZs*x0D6IbOhTmZs&x0D5IbOhTmZs&x0D5IbOgTmZr&x0D5IbOgTmZr&x0C5IbNgTmZr&x0C5IbNgTmYr&x0C5IbNgTmYr&x+C5IaNgTmYr&x+C5IaNgTlYr&w+C5IaNgTlYr&w+C 5HaNgSlYr&w+C5HaNgSlYr%w+C4HaNgSlYr%w+C4HaNfSlYq%w+C4HaNfSlYq#t*y1E7JcPiUn#t*y1E6JcPhUn#t*y1E6JcPhUn#s*y1D6JcPhUn#s*y1D6JcOhUnZs*y1D6JcOhUnZs*y0D6JbOhUnZs*y0D6JbOhUmZs*y0D6JbOhUmZs*x0D6IbOhUmZs*x0D6IbOhTmZs&x0D6IbOhTmZs&x0D5IbOgTmZs&x0D5IbOgTmZr&x0C5IbOgTmZr&x0C5IbNgTmYr&x0C5IbNgTmYr&x+C5IaNgTmYr&x+z2E7KdPiVo!t(z2E7KdPiVo#t(z1E7KdPiVo#t(z1E7KcPiVn#t(z1E7KcPiVn#t(y1E7JcPiVn#t(y1E7JcPiUn#t*y1E7JcPiUn#t*y1E6JcPiUn#t*y1E6JcPhUn#s*y1E6J cPhUn#s*y1D6JcOhUn#s*y1D6JcOhUnZs*y0D6JcOhUnZs*y0D6JbOhUmZs*y0D6JbOhUmZs*x0D6IbOhUmZs*x0D6IbOhTmZs&x0D6IbOhQjWo!u)z2F8LdQjWo!u)z2F8KdQjVo!u)z2F8KdQjVo!u(z2F7KdQjVo!u(z2F7KdQiVo!t(z2F7KdQiVo!t(z2E7KdQiVo!t(z2E7KdPiVo#t(z2E7KdPiVo#t(z1E7KcPiVo#t(z1E7KcPiVn#t(y1E7KcPiVn#t(y1E7JcPiUn#t(y1E7JcPiUn#t*y1E6JcPiUn#t*y1E6JcPhUn#s*y1E6JcPhUn#s*y1D6JcOhUn#s*y1A3G8LeRjWp$v)A3G8LeRjWp$u)A3F8LeRjWp$u)A3F8LeQjWp!u)A3F8LeQjWp!u)A2F8LdQjWp!u)A2F8LdQjWo!u)A2F8LdQj Wo!u)z2F8KdQjWo!u)z2F8KdQjVo!u(z2F8KdQjVo!u(z2F7KdQiVo!u(z2F7KdQiVo!t(z2E7KdQiVo!t(z2E7KdPiVoXq%w-B4H9MfSkXq%v-B4H9MfSkXq%v-B4G9MfRkXq%v-B4G9MfRkXq$v-B3G9MfRkXq$v-B3G9MeRkXp$v-B3G9MeRkXp$v-A3G9LeRkXp$v-A3G9LeRkWp$v-A3G9LeRkWp$v)A3G8LeRkWp$v)A3G8LeRjWp$u)A3G8LeRjWp$u)A3F8LeQgTmYr&x+C5IaNgTlYr&x+C5IaNgTlYr&w+C5HaNgTlYr&w+C5HaNgSlYr%w+C5HaNgSlYr%w+C4HaNfSlYr%w+C4HaNfSlYq%w+B4HaNfSlYq%w+B4HaMfSlXq%w+B4HaMfSlXq%w- B4H9MfSlXq%w-B4H9MfSkXq%v-B4H9MfSkXq%v-B4G9MfSkXq%v-B4G9MfRkXq$v- B4G9JbOhUmZs*x0D6IbOhUmZs*x0D6IbOhTmZs&x0D6IbOhTmZs&x0D5IbOhTmZs&x0D5IbOgTmZr&x0D5IbOgTmZr&x0C5IbNgTmZr&x0C5IbNgTmYr&x+C5IbNgTmYr&x+C5IaNgTlYr&x+C5IaNgTlYr&w+C5HaNgTlYr&t(z1E7KcPiVo#t(z1E7KcPiVn#t(y1E7KcPiVn#t(y1E7JcPiUn#t(y1E7JcPiUn#t*y1E6JcPiUn#t*y1E6JcPhUn#s*y1E6JcPhUn#s*y1D6JcPhUn#s*y1D6JcOhUnZs*y1D6JcOhUnZs*y0D6JbOhUnZs*y0D6JbOhUmZs*x0D6JbOeQjWp!u)A2F8LeQjWp!u)A2F8LdQjWo!u)A2F8LdQjWo!u)z2F8KdQjWo!u)z2F8KdQjVo!u(z2F8KdQjVo!u(z2F7 KdQiVo!u(z2F7KdQiVo!t(z2E7KdQiVo!t(z2E7KdPiVo#t(z2E7KdPiVo#t(z1E7H9MfSkXq%v-B4G9MfRkXq%v-B4G9MfRkXq$v-B3G9MfRkXq$v-B3G9MeRkXp$v-B3G9MeRkXp$v-A3G9LeRkXp$v-A3G9LeRkWp$v-A3G9LeRkWp$v)A3G8LeRkWp$v)A3G8LeRjWp$u)A3G8LeRjWp$u)A3F8LeQjWp$u)A3F8IaNgTlYr&x+C5IaNgTlYr&w+C5HaNgTlYr&w+C5HaNgSlYr%w+C5HaNgSlYr%w+C4HaNfSlYr%w+C4HaNfSlYq%w+B4HaNfSlYq%w+B4HaMfSlXq%w+B4HaMfSlXq%w- B4H9MfSlXq%w*y1D6JcOhUn#s*y1D6JcOhUnZs*y0D6JcOhUnZs*y0D6JbOhUmZs*y0D6JbOhUmZs*x0D6IbOhUmZs*x0D6IbOhTmZs*x0D6